Pfizer, Haleon
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...
4don MSN
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer ...
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback